PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27114800-0 2016 Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance. Docetaxel 16-25 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 27284014-4 2016 We determined that our established PTX-resistant cancer cells display ABCB1/ABCC1-associated cross-resistance to chemically different drugs such as 5-fluorouracil, docetaxel, and cisplatin. Docetaxel 164-173 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 26882453-6 2016 The combination of TXT and TAM could effectively reverse P-gp expression in tumor tissues and provide a significant survival benefit for advanced NSCLC patients compared with TXT alone (11.6 vs. 9.1 months, P=0.030). Docetaxel 19-22 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 26882453-7 2016 In addition, in the TXT+TAM group, patients achieving P-gp reversal had a significantly greater median progression-free survival and overall survival than nonreversal patients. Docetaxel 20-23 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 26882453-9 2016 The combination of TXT and TAM may be an effective and safe treatment option for advanced NSCLC patients who have already developed P-gp-mediated multidrug resistance. Docetaxel 19-22 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 26764117-1 2016 In the present studies locally injectable docetaxel nanocrystals loaded d-alpha tocopheryl polyethylene glycol 1000 succinate-modified Pluronic F127 (DOC-NCs-TPGS-PF127) thermo-sensitive hydrogels were prepared to reverse drug resistance of P-glycoprotein (P-gp)-overexpressing human liver cancer SMMC-7721 tumors. Docetaxel 42-51 ATP binding cassette subfamily B member 1 Homo sapiens 241-255 26764117-1 2016 In the present studies locally injectable docetaxel nanocrystals loaded d-alpha tocopheryl polyethylene glycol 1000 succinate-modified Pluronic F127 (DOC-NCs-TPGS-PF127) thermo-sensitive hydrogels were prepared to reverse drug resistance of P-glycoprotein (P-gp)-overexpressing human liver cancer SMMC-7721 tumors. Docetaxel 42-51 ATP binding cassette subfamily B member 1 Homo sapiens 257-261 27114800-4 2016 In this study, we investigated the role of combination treatments of docetaxel and vinblastine in overcoming P-glycoprotein mediated inhibition of apoptosis and induction of cell proliferation in human non-small cell lung carcinoma cells. Docetaxel 69-78 ATP binding cassette subfamily B member 1 Homo sapiens 109-123 26548759-5 2016 We found that in our OS cell lines this agent was able to revert the ABCB1/ABCC1-mediated resistance against doxorubicin, as well as against the drugs used in second-line OS treatments that are substrates of these transporters (taxotere, etoposide, vinorelbine). Docetaxel 228-236 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 25995342-1 2015 PURPOSE: Previous studies show that inhibition of ABCB1 expression overcomes acquired docetaxel resistance in C4-2B-TaxR cells. Docetaxel 86-95 ATP binding cassette subfamily B member 1 Homo sapiens 50-55 26506423-2 2015 HCT15 and H630R1 cell lines expressing high basal levels of the ABCB1 protein, known to cause multi-drug resistance, were also sensitive to growth inhibition by 1 but were resistant to both vincristine and docetaxel, two commonly used microtubule inhibitors. Docetaxel 206-215 ATP binding cassette subfamily B member 1 Homo sapiens 64-69 26154614-7 2015 In vitro sensitivity to docetaxel inversely correlated with mRNA expression for ABCB1, but the correlation with ABCB1 expression was weaker for cabazitaxel. Docetaxel 24-33 ATP binding cassette subfamily B member 1 Homo sapiens 80-85 26027763-0 2015 Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer. Docetaxel 64-73 ATP binding cassette subfamily B member 1 Homo sapiens 15-29 26027763-1 2015 OBJECTIVES: Docetaxel is used as the first-line chemotherapy for castration-resistant prostate cancer (CRPC), but docetaxel resistance occurs in part owing to induction of P-glycoprotein (P-gp) encoded by multidrug resistance protein 1 (MDR1) gene. Docetaxel 114-123 ATP binding cassette subfamily B member 1 Homo sapiens 172-186 26027763-1 2015 OBJECTIVES: Docetaxel is used as the first-line chemotherapy for castration-resistant prostate cancer (CRPC), but docetaxel resistance occurs in part owing to induction of P-glycoprotein (P-gp) encoded by multidrug resistance protein 1 (MDR1) gene. Docetaxel 114-123 ATP binding cassette subfamily B member 1 Homo sapiens 188-192 26027763-1 2015 OBJECTIVES: Docetaxel is used as the first-line chemotherapy for castration-resistant prostate cancer (CRPC), but docetaxel resistance occurs in part owing to induction of P-glycoprotein (P-gp) encoded by multidrug resistance protein 1 (MDR1) gene. Docetaxel 114-123 ATP binding cassette subfamily B member 1 Homo sapiens 205-235 26027763-1 2015 OBJECTIVES: Docetaxel is used as the first-line chemotherapy for castration-resistant prostate cancer (CRPC), but docetaxel resistance occurs in part owing to induction of P-glycoprotein (P-gp) encoded by multidrug resistance protein 1 (MDR1) gene. Docetaxel 114-123 ATP binding cassette subfamily B member 1 Homo sapiens 237-241 26027763-4 2015 In this study, we aimed to investigate if P-gp in blood exosomes could be a marker to diagnose docetaxel resistance and select a taxoid for patients with CRPC. Docetaxel 95-104 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 26027763-10 2015 Cabazitaxel effectively killed PC-3R cells, and MDR1 knockdown improved the sensitivity of PC-3R cells to docetaxel but not to cabazitaxel. Docetaxel 106-115 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 26027763-11 2015 The P-gp level in blood exosomes was relatively higher in clinically docetaxel-resistant patients than in therapy-naive patients. Docetaxel 69-78 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 26027763-12 2015 CONCLUSIONS: Our results suggest that detection of P-gp in blood exosomes, which is involved in resistance to docetaxel but not to cabazitaxel, could be useful to diagnose docetaxel resistance and select an appropriate taxoid for patients with CRPC-docetaxel or cabazitaxel. Docetaxel 110-119 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 26027763-12 2015 CONCLUSIONS: Our results suggest that detection of P-gp in blood exosomes, which is involved in resistance to docetaxel but not to cabazitaxel, could be useful to diagnose docetaxel resistance and select an appropriate taxoid for patients with CRPC-docetaxel or cabazitaxel. Docetaxel 172-181 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 26027763-12 2015 CONCLUSIONS: Our results suggest that detection of P-gp in blood exosomes, which is involved in resistance to docetaxel but not to cabazitaxel, could be useful to diagnose docetaxel resistance and select an appropriate taxoid for patients with CRPC-docetaxel or cabazitaxel. Docetaxel 172-181 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 25648089-7 2015 There were significant associations between docetaxel-induced leucopenia and 2677G/T of ABCB1 and rs12762549 of ABCC2 (p=0.025 and p=0.028, respectively). Docetaxel 44-53 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 25648089-8 2015 In a multivariate analysis, we observed that patients carrying 2677G>T in ABCB1might be associated with higher risk of chemo-resistance when treated with docetaxel (odds ratio [OR], 6.48; confidence interval, 1.92 to 21.94; p=0.003). Docetaxel 157-166 ATP binding cassette subfamily B member 1 Homo sapiens 77-82 25648089-10 2015 CONCLUSION: Our data suggest that ABCB1 (2677G/T) and SLCO1B3 (rs11055585) might be major genetic predictors of docetaxel-related toxicities in patients receiving docetaxel chemotherapy. Docetaxel 112-121 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 25648089-10 2015 CONCLUSION: Our data suggest that ABCB1 (2677G/T) and SLCO1B3 (rs11055585) might be major genetic predictors of docetaxel-related toxicities in patients receiving docetaxel chemotherapy. Docetaxel 163-172 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 25596703-0 2015 Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. Docetaxel 15-24 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 26057062-0 2015 Prostate cancer: Antiandrogens reverse docetaxel resistance via ABCB1 inhibition. Docetaxel 39-48 ATP binding cassette subfamily B member 1 Homo sapiens 64-69 24888374-0 2015 EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Docetaxel 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 121-126 25932627-8 2015 The Kp for digoxin, verapamil and docetaxel were 2, 16 and 2-times higher in the hMDR1 compared to the C57BL/6 WT mice. Docetaxel 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 81-86 24888374-0 2015 EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Docetaxel 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 24888374-14 2015 Moreover, EGFR-mediated docetaxel resistance occurred through the Akt-dependent ABCB1 expression in PC cells. Docetaxel 24-33 ATP binding cassette subfamily B member 1 Homo sapiens 80-85 25760729-7 2015 All results suggested that epigenetic downregulation of DKK3 leads to docetaxel resistance in human nonsmall cell lung cancer (NSCLC) cells by increased expression of P-glycoprotein. Docetaxel 70-79 ATP binding cassette subfamily B member 1 Homo sapiens 167-181 25410489-0 2015 ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Docetaxel 79-88 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 25410489-9 2015 ABCB1 3435TT genotype had a higher AUC than CC/CT for docetaxel. Docetaxel 54-63 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 23364915-10 2013 A docetaxel-resistant cell line was selected (MDR-1(+), CD133(+)) by continuous exposure to docetaxel. Docetaxel 2-11 ATP binding cassette subfamily B member 1 Homo sapiens 46-51 23928571-5 2013 Accordingly, we investigated the pharmacokinetic interactions of the classic cytotoxics and p-glycoprotein substrates docetaxel and doxorubicin when administered concurrently with the targeted agent and p-glycoprotein inhibitor lapatinib. Docetaxel 118-127 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 24883107-4 2014 Cabazitaxel, a third-generation taxane, was chosen for clinical development based on its decreased affinity for the drug efflux pump, p-glycoprotein, which is a frequent cause of drug resistance in docetaxel-resistant preclinical models. Docetaxel 198-207 ATP binding cassette subfamily B member 1 Homo sapiens 134-148 24219005-1 2014 INTRODUCTION: Previously, we demonstrated that oral docetaxel plus the P-glycoprotein (Pgp; ABCB1) inhibitor cyclosporin A (CsA) is safe and results in adequate exposure to docetaxel. Docetaxel 173-182 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 24219005-1 2014 INTRODUCTION: Previously, we demonstrated that oral docetaxel plus the P-glycoprotein (Pgp; ABCB1) inhibitor cyclosporin A (CsA) is safe and results in adequate exposure to docetaxel. Docetaxel 173-182 ATP binding cassette subfamily B member 1 Homo sapiens 87-90 23861346-0 2013 Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Docetaxel 50-59 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 23861346-7 2013 The role of ABCB1 in the development of docetaxel resistance was examined. Docetaxel 40-49 ATP binding cassette subfamily B member 1 Homo sapiens 12-17 23861346-8 2013 Knockdown of ABCB1 expression by its specific shRNA or inhibitor resensitized docetaxel-resistant TaxR cells to docetaxel treatment by enhancing apoptotic cell death. Docetaxel 78-87 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 23861346-8 2013 Knockdown of ABCB1 expression by its specific shRNA or inhibitor resensitized docetaxel-resistant TaxR cells to docetaxel treatment by enhancing apoptotic cell death. Docetaxel 112-121 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 23861346-10 2013 Collectively, these results suggest that overexpression of ABCB1 mediates acquired docetaxel resistance and targeting ABCB1 expression could be a potential approach to resensitize docetaxel-resistant prostate cancer cells to docetaxel treatment. Docetaxel 83-92 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 23861346-10 2013 Collectively, these results suggest that overexpression of ABCB1 mediates acquired docetaxel resistance and targeting ABCB1 expression could be a potential approach to resensitize docetaxel-resistant prostate cancer cells to docetaxel treatment. Docetaxel 180-189 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 23861346-10 2013 Collectively, these results suggest that overexpression of ABCB1 mediates acquired docetaxel resistance and targeting ABCB1 expression could be a potential approach to resensitize docetaxel-resistant prostate cancer cells to docetaxel treatment. Docetaxel 180-189 ATP binding cassette subfamily B member 1 Homo sapiens 118-123 23861346-10 2013 Collectively, these results suggest that overexpression of ABCB1 mediates acquired docetaxel resistance and targeting ABCB1 expression could be a potential approach to resensitize docetaxel-resistant prostate cancer cells to docetaxel treatment. Docetaxel 180-189 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 23861346-10 2013 Collectively, these results suggest that overexpression of ABCB1 mediates acquired docetaxel resistance and targeting ABCB1 expression could be a potential approach to resensitize docetaxel-resistant prostate cancer cells to docetaxel treatment. Docetaxel 180-189 ATP binding cassette subfamily B member 1 Homo sapiens 118-123 23364915-10 2013 A docetaxel-resistant cell line was selected (MDR-1(+), CD133(+)) by continuous exposure to docetaxel. Docetaxel 92-101 ATP binding cassette subfamily B member 1 Homo sapiens 46-51 23683834-2 2013 Structure-activity relationship analysis showed that aromatic substituted aliphatic amine at the 24-positions (groups V) effectively and significantly sensitized P-gp overexpressing multidrug resistant (MDR) cells to anticancer drugs, such as docetaxel (DOC), vincristine (VCR), and adriamycin (ADM). Docetaxel 243-252 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 21795074-3 2013 We first hypothesized an effect of vandetanib in modulation the function of MDR1, leading to a longer retention of docetaxel inside the cell. Docetaxel 115-124 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 21795074-5 2013 MATERIALS AND METHODS: We used PC3 cells either wild type (PC3wt) or with acquired resistance to docetaxel (PC3R), characterized by a higher expression of MDR1. Docetaxel 97-106 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 23683834-2 2013 Structure-activity relationship analysis showed that aromatic substituted aliphatic amine at the 24-positions (groups V) effectively and significantly sensitized P-gp overexpressing multidrug resistant (MDR) cells to anticancer drugs, such as docetaxel (DOC), vincristine (VCR), and adriamycin (ADM). Docetaxel 254-257 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 23666532-1 2013 We have previously reported an association between ABCB1 C3435T polymorphism and docetaxel pharmacokinetics in breast cancer patients. Docetaxel 81-90 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 22426195-1 2013 UNLABELLED: Docetaxel is used in the treatment of many types of cancer, but its entry into the brain is restricted by p-glycoprotein (p-gp) efflux. Docetaxel 12-21 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 23053273-8 2013 Responsiveness to taxotere was related to reduced levels of ABCB1, ABCC2, ABCG1, ABCG2, and MVP mRNA in tumor samples collected after chemotherapy. Docetaxel 18-26 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 22426195-1 2013 UNLABELLED: Docetaxel is used in the treatment of many types of cancer, but its entry into the brain is restricted by p-glycoprotein (p-gp) efflux. Docetaxel 12-21 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 22426195-2 2013 A potential drug-drug interaction exists between docetaxel and ketoconazole because both agents are metabolized hepatically by the cytochrome P-450 system, and ketoconazole can inhibit p-gp efflux of docetaxel at blood brain barrier. Docetaxel 49-58 ATP binding cassette subfamily B member 1 Homo sapiens 185-189 22426195-2 2013 A potential drug-drug interaction exists between docetaxel and ketoconazole because both agents are metabolized hepatically by the cytochrome P-450 system, and ketoconazole can inhibit p-gp efflux of docetaxel at blood brain barrier. Docetaxel 200-209 ATP binding cassette subfamily B member 1 Homo sapiens 185-189 21720762-10 2012 However, docetaxel resistance in MCF-7/120nM DOC were more complicated with the involvement of ECM related gene expression, cytokine and growth factor signaling, ROS metabolism and EMT related gene expression together with higher level of MDR1 expression. Docetaxel 9-18 ATP binding cassette subfamily B member 1 Homo sapiens 239-243 22445862-4 2012 We demonstrated that p53 is induced by low dose DOC treatment, resulting in MDR-1 gene suppression in human lung cancer cells. Docetaxel 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 76-81 22572929-3 2012 Functional P-gp can confer resistance to activate caspase-8 and -3 dependent apoptosis induced by a range of different stimuli, including tumor necrosis and chemotherapeutic drugs such as docetaxel and vincristine. Docetaxel 188-197 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 22572929-4 2012 We demonstrated here that comparison of sensitive KB cells, P-gp positive (P-gp(+ve)) KBv200 cells were extremely resistant to apoptosis induced by docetaxel. Docetaxel 148-157 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 22572929-4 2012 We demonstrated here that comparison of sensitive KB cells, P-gp positive (P-gp(+ve)) KBv200 cells were extremely resistant to apoptosis induced by docetaxel. Docetaxel 148-157 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 22572929-5 2012 FG020326, a pharmacological inhibitor of P-gp function, could enhance concentration-dependently the effect of docetaxel on cell apoptosis and sensitize caspase-8, -9 and -3 activation in P-gp overexpressing KBv200 cells, but not in KB cells. Docetaxel 110-119 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 22572929-6 2012 Therefore, the enhancement of caspase-8, -9 and -3 activation induced by docetaxel may be one of the key mechanisms of the reversal of P-gp mediated docetaxel resistance by FG020326. Docetaxel 73-82 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 22572929-6 2012 Therefore, the enhancement of caspase-8, -9 and -3 activation induced by docetaxel may be one of the key mechanisms of the reversal of P-gp mediated docetaxel resistance by FG020326. Docetaxel 149-158 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 22271208-10 2012 DISCUSSION: Although ABCB1 3435 T/T was significantly associated with docetaxel-related neutropenia in our study population, polymorphism of pharmacogenetic genes related to docetaxel metabolism did not appear to be evidently associated with docetaxel-related adverse events. Docetaxel 70-79 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 22294184-8 2012 Strikingly, docetaxel-resistant HGT-1 cell derivatives overexpressing the MDR-1 gene were much more sensitive to lovastatin than docetaxel-sensitive cells. Docetaxel 12-21 ATP binding cassette subfamily B member 1 Homo sapiens 74-79 21505085-3 2012 The pharmacokinetics of docetaxel are determined by the activity of the metabolizing enzyme cytochrome P450 3A (CYP3A) and the drug efflux transporter P-glycoprotein (P-gp). Docetaxel 24-33 ATP binding cassette subfamily B member 1 Homo sapiens 151-165 21505085-3 2012 The pharmacokinetics of docetaxel are determined by the activity of the metabolizing enzyme cytochrome P450 3A (CYP3A) and the drug efflux transporter P-glycoprotein (P-gp). Docetaxel 24-33 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 22294184-8 2012 Strikingly, docetaxel-resistant HGT-1 cell derivatives overexpressing the MDR-1 gene were much more sensitive to lovastatin than docetaxel-sensitive cells. Docetaxel 129-138 ATP binding cassette subfamily B member 1 Homo sapiens 74-79 22011009-10 2011 Expression level of mdr1 gene was downregulated after resveratrol combined with doxorubicin or docetaxel in all tested cell lines. Docetaxel 95-104 ATP binding cassette subfamily B member 1 Homo sapiens 20-24 23493035-5 2012 Immonofluorescent technique was used to show MDR-1 protein in MDA-MB-231 and MCF-7 cells after treatment with DOX or DOCT. Docetaxel 117-121 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 23493035-8 2012 Immonofluorescent results confirmed the expression of MDR-1 in these two cell lines after DOX or DOCT treatment. Docetaxel 97-101 ATP binding cassette subfamily B member 1 Homo sapiens 54-59 23251413-7 2012 Exosomes expelled from DU145 and 22Rv1 docetaxel-resistant variants (DU145RD and 22Rv1RD) conferred docetaxel-resistance to DU145, 22Rv1 and LNCap cells, which may be partly due to exosomal MDR-1/P-gp transfer. Docetaxel 39-48 ATP binding cassette subfamily B member 1 Homo sapiens 190-195 23251413-7 2012 Exosomes expelled from DU145 and 22Rv1 docetaxel-resistant variants (DU145RD and 22Rv1RD) conferred docetaxel-resistance to DU145, 22Rv1 and LNCap cells, which may be partly due to exosomal MDR-1/P-gp transfer. Docetaxel 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 190-195 21468756-8 2011 CONCLUSIONS: This study suggests that the cooperative influence of functional polymorphisms in SLCO1B3 and ABCB1 genes may be responsible for the interindividual variability in docetaxel disposition in Asian nasopharyngeal cancer patients. Docetaxel 177-186 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 21468756-1 2011 PURPOSE: This exploratory study aimed to explain the interindividual variabilities of docetaxel pharmacokinetics and pharmacodynamics in Asian nasopharyngeal carcinoma patients (n = 54) through the genotyping of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 genes. Docetaxel 86-95 ATP binding cassette subfamily B member 1 Homo sapiens 228-233 20829196-7 2010 Interestingly, multidrug-resistant cell lines that overexpressed P-glycoprotein (P-gp), multidrug resistance-associated proteins, and breast cancer resistance protein were rendered resistant to docetaxel, vinblastine, SN-38, and doxorubicin, but not to I-387. Docetaxel 194-203 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 21262849-5 2011 Overexpression of P-gp also resulted in significantly decreased cell susceptibility to docetaxel, paclitaxel, and vinblastine. Docetaxel 87-96 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 21695098-4 2011 In the last year, cabazitaxel, a novel taxane with decreased affinity for ATP-dependent drug efflux pump P-glycoprotein, became the first cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory disease, and has received regulatory approval for treatment in this setting. Docetaxel 208-217 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 21448449-5 2011 Cabazitaxel is a novel tubulin-binding taxane that differs from docetaxel because of its poor affinity for P-glycoprotein (P-gp), an ATP-dependent drug efflux pump. Docetaxel 64-73 ATP binding cassette subfamily B member 1 Homo sapiens 107-121 21448449-5 2011 Cabazitaxel is a novel tubulin-binding taxane that differs from docetaxel because of its poor affinity for P-glycoprotein (P-gp), an ATP-dependent drug efflux pump. Docetaxel 64-73 ATP binding cassette subfamily B member 1 Homo sapiens 123-127 21448449-6 2011 Cancer cells that express P-gp become resistant to taxanes, and the effectiveness of docetaxel can be limited by its high substrate affinity for P-gp. Docetaxel 85-94 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 21448449-6 2011 Cancer cells that express P-gp become resistant to taxanes, and the effectiveness of docetaxel can be limited by its high substrate affinity for P-gp. Docetaxel 85-94 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 20829196-7 2010 Interestingly, multidrug-resistant cell lines that overexpressed P-glycoprotein (P-gp), multidrug resistance-associated proteins, and breast cancer resistance protein were rendered resistant to docetaxel, vinblastine, SN-38, and doxorubicin, but not to I-387. Docetaxel 194-203 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 19001875-0 2008 Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells. Docetaxel 122-131 ATP binding cassette subfamily B member 1 Homo sapiens 24-29 20041327-7 2010 RESULTS: Our study showed that vincristine, tamoxifen, vinblastine, docetaxel, cyclophosphamide, flutamide, ifosfamide and paclitaxel activate PXR-mediated Pgp induction, and were additionally shown to affect the intracellular accumulation of the Pgp probe rhodamine 123. Docetaxel 68-77 ATP binding cassette subfamily B member 1 Homo sapiens 156-159 20041327-7 2010 RESULTS: Our study showed that vincristine, tamoxifen, vinblastine, docetaxel, cyclophosphamide, flutamide, ifosfamide and paclitaxel activate PXR-mediated Pgp induction, and were additionally shown to affect the intracellular accumulation of the Pgp probe rhodamine 123. Docetaxel 68-77 ATP binding cassette subfamily B member 1 Homo sapiens 247-250 20628376-0 2010 Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Docetaxel 39-48 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 20628376-2 2010 Docetaxel is a substrate for ABCB1 whose function has been shown to be modulated by oestrogen and progesterone. Docetaxel 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 29-34 20628376-3 2010 METHODS: Whether ABCB1 polymorphisms including T-129C, A61G, C1236T, G2677T/A and C3435T polymorphisms could account for variations in the disposition of docetaxel and whether menopausal status at the time of diagnosis might interact with this effect were analysed in women receiving neoadjuvant chemotherapy for breast cancer (n=86). Docetaxel 154-163 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 19332043-0 2009 Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Docetaxel 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 100-105 19262372-0 2009 Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Docetaxel 38-47 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 19262372-0 2009 Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Docetaxel 102-111 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 19262372-12 2009 The simultaneous administration of a P-gp inhibitor may prevent docetaxel efflux, thereby sensitizing cells to docetaxel and other chemotherapeutic agents. Docetaxel 64-73 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 19262372-12 2009 The simultaneous administration of a P-gp inhibitor may prevent docetaxel efflux, thereby sensitizing cells to docetaxel and other chemotherapeutic agents. Docetaxel 111-120 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 18812689-0 2009 MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Docetaxel 91-100 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 18812689-3 2009 OBJECTIVES: To investigate whether the MDR1 2677 and 3435 genotypes are associated with the sensitivity of non-small-cell lung cancer (NSCLC) to docetaxel. Docetaxel 145-154 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 18812689-9 2009 CONCLUSION: Our findings suggest that the MDR1 2677G>T/A polymorphism and the 2677G-3435C haplotype are predictors of treatment response to docetaxel-cisplatin chemotherapy in NSCLC patients. Docetaxel 143-152 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 19001875-3 2008 During selection of MCF-7 cells for survival in increasing concentrations of docetaxel (MCF-7TXT cells), we observed in this study a temporal correlation between the acquisition of docetaxel resistance at selection dose 9 and the increased expression of ABCB1. Docetaxel 77-86 ATP binding cassette subfamily B member 1 Homo sapiens 254-259 19001875-3 2008 During selection of MCF-7 cells for survival in increasing concentrations of docetaxel (MCF-7TXT cells), we observed in this study a temporal correlation between the acquisition of docetaxel resistance at selection dose 9 and the increased expression of ABCB1. Docetaxel 181-190 ATP binding cassette subfamily B member 1 Homo sapiens 254-259 19001875-10 2008 Taken together, our findings suggest that the increased expression of ABCB1 upon acquisition of docetaxel resistance in breast tumor cells can be multifactorial, involving both epigenetic changes in promoter usage and regional chromosome amplification. Docetaxel 96-105 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 18063021-9 2008 Specifically, the PK of DOC was correlated with the ratio of CYP4A5 to ABCB1 gene expression, thus representing a novel mechanism of chemotherapy resistance. Docetaxel 24-27 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 17876342-2 2008 We genotyped the transcriptional regulators of CYP3A and ABCB1 in 101 breast cancer patients from 3 Asian ethnic groups, that is, Chinese, Malays and Indians, in correlation with the pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin. Docetaxel 224-233 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 18281755-8 2008 Recent studies in this area have demonstrated various mechanisms involved in the anti-tumor activity of docetaxel: (1) efflux (p-glycoprotein), (2) metabolism (CYP3A4), (3) beta-tubulin (isotype class I and III), (4) cell cycle (HER2, BRCA1), (5) apoptosis (p53, Bcl-2, thioredoxin), and (6) cell proliferation (MIB-1, nuclear grade). Docetaxel 104-113 ATP binding cassette subfamily B member 1 Homo sapiens 127-143 18628469-0 2008 ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Docetaxel 136-145 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 18628469-1 2008 PURPOSE: Polymorphisms that are associated with ABCB1 expression and function may be linked to treatment efficacy and the development of neutropenia and neurotoxicity in patients with androgen-independent prostate cancer receiving docetaxel. Docetaxel 231-240 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 18628469-9 2008 CONCLUSION: The data suggest that docetaxel-induced neuropathy, neutropenia grade, and overall survival could be linked to ABCB1 allelic variants with ensuing negative implications for docetaxel treatment in patients carrying ABCB1 variant genotypes. Docetaxel 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 18628469-9 2008 CONCLUSION: The data suggest that docetaxel-induced neuropathy, neutropenia grade, and overall survival could be linked to ABCB1 allelic variants with ensuing negative implications for docetaxel treatment in patients carrying ABCB1 variant genotypes. Docetaxel 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 226-231 18628469-9 2008 CONCLUSION: The data suggest that docetaxel-induced neuropathy, neutropenia grade, and overall survival could be linked to ABCB1 allelic variants with ensuing negative implications for docetaxel treatment in patients carrying ABCB1 variant genotypes. Docetaxel 185-194 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 18628469-9 2008 CONCLUSION: The data suggest that docetaxel-induced neuropathy, neutropenia grade, and overall survival could be linked to ABCB1 allelic variants with ensuing negative implications for docetaxel treatment in patients carrying ABCB1 variant genotypes. Docetaxel 185-194 ATP binding cassette subfamily B member 1 Homo sapiens 226-231 15316750-2 2005 Previous studies have indicated that the intestinal efflux pump P-glycoprotein (P-gp) prevents uptake from the gut resulting in low systemic exposure to docetaxel. Docetaxel 153-162 ATP binding cassette subfamily B member 1 Homo sapiens 64-78 17683514-8 2007 During docetaxel chemotherapy, an increase in the rate of MDR1-transduced leukocytes (up to 10%) was observed. Docetaxel 7-16 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 17683514-9 2007 Comparison of docetaxel-induced granulocytopenia in the two patients suggested a bone marrow-protective effect of the MDR1-transduced cells. Docetaxel 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 17907967-4 2007 After 10 cycles of docetaxel (days 71-316), MDR1 transgene levels were found to have increased, and then decreased to undetectable levels by day 1461. Docetaxel 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 17907967-10 2007 Our results thus show that docetaxel may have been effective in promoting the expansion of several MDR1-transduced clones in patient 1, but that they persist in the peripheral blood for only a few years. Docetaxel 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 17256132-2 2007 Furthermore, docetaxel is also a substrate for the transmembrane ATP-binding cassette efflux transporter protein ABCB1. Docetaxel 13-22 ATP binding cassette subfamily B member 1 Homo sapiens 113-118 17256132-5 2007 To further elucidate the role of CYP3A- and ABCB1-mediated elimination pathways for docetaxel we investigated the effect of the potent CYP3A-inhibitor, and also ABCB1-inhibitor, ketoconazole on the fecal and urinary disposition of docetaxel in cancer patients. Docetaxel 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 17020985-0 2006 Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Docetaxel 91-100 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 17020985-4 2006 The aim of this study was therefore to investigate the influence of polymorphisms in the CYP3A and ABCB1 genes on the population pharmacokinetics of docetaxel. Docetaxel 149-158 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 17020985-11 2006 The homozygous C1236T polymorphism in the ABCB1 gene (ABCB1*8) was significantly correlated with a decreased docetaxel clearance (-25%; P = 0.0039). Docetaxel 109-118 ATP binding cassette subfamily B member 1 Homo sapiens 42-47 17020985-11 2006 The homozygous C1236T polymorphism in the ABCB1 gene (ABCB1*8) was significantly correlated with a decreased docetaxel clearance (-25%; P = 0.0039). Docetaxel 109-118 ATP binding cassette subfamily B member 1 Homo sapiens 54-59 17020985-14 2006 CONCLUSIONS: The polymorphism C1236T in the ABCB1 gene was significantly related to docetaxel clearance. Docetaxel 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 16529050-5 2006 Three patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. Docetaxel 94-103 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 16518057-6 2006 Two patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. Docetaxel 92-101 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 15955594-8 2005 However, clinically achievable levels of gefitinib moderately reversed the Pgp-mediated resistance to paclitaxel and docetaxel in Pgp overexpressing cells. Docetaxel 117-126 ATP binding cassette subfamily B member 1 Homo sapiens 75-78 15955594-8 2005 However, clinically achievable levels of gefitinib moderately reversed the Pgp-mediated resistance to paclitaxel and docetaxel in Pgp overexpressing cells. Docetaxel 117-126 ATP binding cassette subfamily B member 1 Homo sapiens 130-133 15643508-5 2005 We examined the association between Bcl-2 and P-gp expression and in vitro chemosensitivity to DOC and CDDP. Docetaxel 95-98 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 15643508-8 2005 Interestingly, although DOC, but not CDDP has been reported to be a substrate of P-gp, P-gp expression was significantly inversely correlated with CDDP sensitivity in pulmonary adenocarcinomas (p=0.03). Docetaxel 24-27 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 17912240-4 2007 Here, we show that clinically achievable levels of ZD6474 reverse P-gp-mediated MDR of the P-gp-overexpressing cell lines derived from breast cancer, MCF-7/adriamycin (ADR), and human oral epidermoid carcinoma, KBV200 to ADR, docetaxel, and vinorelbine. Docetaxel 226-235 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 17912240-4 2007 Here, we show that clinically achievable levels of ZD6474 reverse P-gp-mediated MDR of the P-gp-overexpressing cell lines derived from breast cancer, MCF-7/adriamycin (ADR), and human oral epidermoid carcinoma, KBV200 to ADR, docetaxel, and vinorelbine. Docetaxel 226-235 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 16805818-8 2006 Various biological parameters have been studied clinically for their ability to predict response to docetaxel, such as parameters related to: (1) efflux (p-glycoprotein) and metabolism (CYP3A4); (2) beta-tubulin (somatic mutation of beta-tubulin and changes in beta-tubulin isotypes levels); (3) cell cycle (HER2, BRCA1 and Aurora-A); and (4) apoptosis (p53, BCL2 and thioredoxin). Docetaxel 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 154-168 17657173-7 2006 SNU-449, the most resistant cell line and the only one overexpressing P-glycoprotein, was 3- to 39-fold more resistant to paclitaxel, docetaxel, and doxorubicin than were other cell lines. Docetaxel 134-143 ATP binding cassette subfamily B member 1 Homo sapiens 70-84 15773348-5 2005 2 patients have been treated so far, and in vivo enrichment of mdr1-transduced cells with docetaxel treatment was seen. Docetaxel 90-99 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 15316750-2 2005 Previous studies have indicated that the intestinal efflux pump P-glycoprotein (P-gp) prevents uptake from the gut resulting in low systemic exposure to docetaxel. Docetaxel 153-162 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 15316750-3 2005 The purpose of this study was to determine the degree of enhancement of the oral uptake of docetaxel on combination with orally administered OC144-093, a potent P-gp inhibitor. Docetaxel 91-100 ATP binding cassette subfamily B member 1 Homo sapiens 161-165 15316750-4 2005 Furthermore, the safety of combined treatment was determined and whether known functional genetic polymorphisms of the MDR1 gene could be associated with variability in docetaxel pharmacokinetics was also investigated. Docetaxel 169-178 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 15316750-22 2005 More patients should be evaluated to determine the effect of P-gp single nucleotide polymorphisms on oral pharmacokinetic values of docetaxel. Docetaxel 132-141 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 14617793-2 2003 Although the cytotoxic taxanes paclitaxel and docetaxel are substrates for Pgp-mediated efflux, the semisynthetic taxane analogue ortataxel inhibits drug efflux mediated by Pgp as well as, as we recently demonstrated, MRP-1 and BCRP. Docetaxel 46-55 ATP binding cassette subfamily B member 1 Homo sapiens 75-78 14610615-11 2004 The gene expression of MDR-1 increased after exposure to DTX in KF and KFTx cells. Docetaxel 57-60 ATP binding cassette subfamily B member 1 Homo sapiens 23-28 15060738-1 2004 PURPOSE: The taxanes paclitaxel and docetaxel are substrates for P-glycoprotein (Pgp), an ATP-binding cassette (ABC) transport protein associated with multidrug resistance (MDR). Docetaxel 36-45 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 15060738-1 2004 PURPOSE: The taxanes paclitaxel and docetaxel are substrates for P-glycoprotein (Pgp), an ATP-binding cassette (ABC) transport protein associated with multidrug resistance (MDR). Docetaxel 36-45 ATP binding cassette subfamily B member 1 Homo sapiens 81-84 12722676-4 2003 We have started a clinical study of gene therapy for breast cancer using multidrug resistance gene (MDR1), in which advanced or relapsed breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hemopoietic cells, and then were treated with docetaxel. Docetaxel 325-334 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 12722676-4 2003 We have started a clinical study of gene therapy for breast cancer using multidrug resistance gene (MDR1), in which advanced or relapsed breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hemopoietic cells, and then were treated with docetaxel. Docetaxel 325-334 ATP binding cassette subfamily B member 1 Homo sapiens 263-267 12722676-5 2003 Two patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment after PBSCT was seen in both cases. Docetaxel 92-101 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Docetaxel 178-186 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 10639573-6 2000 Differing from MMC, MGMT was shown to participate in the resistance of Topo I inhibitors (CPT-11, SN-38 and DX-8951f), while GSTpi and MDR1 were involved in docetaxel (TXT) resistance. Docetaxel 157-166 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 10639573-6 2000 Differing from MMC, MGMT was shown to participate in the resistance of Topo I inhibitors (CPT-11, SN-38 and DX-8951f), while GSTpi and MDR1 were involved in docetaxel (TXT) resistance. Docetaxel 168-171 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 12008197-0 2002 Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Docetaxel 15-24 ATP binding cassette subfamily B member 1 Homo sapiens 44-58 12121008-1 2002 P-glycoprotein (P-GP)-based multidrug resistance (MDR) and undesirable side effects are significant drawbacks to the clinical use of paclitaxel and docetaxel. Docetaxel 148-157 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 12121008-1 2002 P-glycoprotein (P-GP)-based multidrug resistance (MDR) and undesirable side effects are significant drawbacks to the clinical use of paclitaxel and docetaxel. Docetaxel 148-157 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 11839680-2 2002 Expression of P-glycoprotein (P-gp) in cancer cells causes resistance against paclitaxel and docetaxel, as well as against vincristine and doxorubicin (ADM). Docetaxel 93-102 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 11839680-2 2002 Expression of P-glycoprotein (P-gp) in cancer cells causes resistance against paclitaxel and docetaxel, as well as against vincristine and doxorubicin (ADM). Docetaxel 93-102 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 11839680-4 2002 In this paper, we report the combined effect of MS-209 with docetaxel in various MDR cancer cell lines that express P-gp. Docetaxel 60-69 ATP binding cassette subfamily B member 1 Homo sapiens 116-120 11181682-1 2001 PURPOSE: Oral bioavailability of docetaxel is very low, which is, at least in part, due to its affinity for the intestinal drug efflux pump P-glycoprotein (P-gp). Docetaxel 33-42 ATP binding cassette subfamily B member 1 Homo sapiens 140-154 11181682-1 2001 PURPOSE: Oral bioavailability of docetaxel is very low, which is, at least in part, due to its affinity for the intestinal drug efflux pump P-glycoprotein (P-gp). Docetaxel 33-42 ATP binding cassette subfamily B member 1 Homo sapiens 156-160 11181682-3 2001 The purpose of this study was to enhance the systemic exposure to oral docetaxel on coadministration of cyclosporine (CsA), an efficacious inhibitor of P-gp and substrate for CYP 3A4. Docetaxel 71-80 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Docetaxel 178-186 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Docetaxel 178-186 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 10576649-1 1999 The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold. Docetaxel 292-300 ATP binding cassette subfamily B member 1 Homo sapiens 26-40 10665657-0 1999 Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Docetaxel 15-24 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 10665657-0 1999 Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Docetaxel 27-35 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 10665657-1 1999 The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. Docetaxel 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 10665657-1 1999 The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. Docetaxel 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 10665657-1 1999 The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. Docetaxel 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 10665657-1 1999 The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. Docetaxel 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 241-245 10665657-1 1999 The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. Docetaxel 31-39 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 10665657-1 1999 The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. Docetaxel 31-39 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 10665657-6 1999 These observations demonstrated that docetaxel is a substrate for human P-gp, suggesting that docetaxel-drug interactions occur via P-gp. Docetaxel 37-46 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 10665657-6 1999 These observations demonstrated that docetaxel is a substrate for human P-gp, suggesting that docetaxel-drug interactions occur via P-gp. Docetaxel 37-46 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 10665657-6 1999 These observations demonstrated that docetaxel is a substrate for human P-gp, suggesting that docetaxel-drug interactions occur via P-gp. Docetaxel 94-103 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 10665657-6 1999 These observations demonstrated that docetaxel is a substrate for human P-gp, suggesting that docetaxel-drug interactions occur via P-gp. Docetaxel 94-103 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 10665657-7 1999 The inhibition of [14C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine, was also found in LLC-PK1 cells, which endogenously express P-gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC-GA5-COL150 cells. Docetaxel 23-32 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 10576649-1 1999 The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold. Docetaxel 292-300 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 10665657-8 1999 These observations indicate that it is necessary to consider the pharmacokinetic and pharmacodynamic interactions of docetaxel via P-gp. Docetaxel 117-126 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 21544450-0 1996 P-glycoprotein-associated resistance to taxol and taxotere and its reversal by dexniguldipine-HCl, dexverapamil-HCl, or cyclosporin A. Docetaxel 50-58 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 9062411-8 1997 While an antagonistic effect on P-glycoprotein (P-gp) activity may contribute to the synergistic effect of tamoxifen and docetaxel on CEM-VBLr and MCF-7 ADRr, other mechanisms must be involved, as the synergistic effect is also apparent with a P-gp-negative cell line. Docetaxel 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 32-46 9062411-8 1997 While an antagonistic effect on P-glycoprotein (P-gp) activity may contribute to the synergistic effect of tamoxifen and docetaxel on CEM-VBLr and MCF-7 ADRr, other mechanisms must be involved, as the synergistic effect is also apparent with a P-gp-negative cell line. Docetaxel 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 9062411-8 1997 While an antagonistic effect on P-glycoprotein (P-gp) activity may contribute to the synergistic effect of tamoxifen and docetaxel on CEM-VBLr and MCF-7 ADRr, other mechanisms must be involved, as the synergistic effect is also apparent with a P-gp-negative cell line. Docetaxel 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 244-248 9864431-1 1999 GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). Docetaxel 191-199 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 9864431-1 1999 GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). Docetaxel 191-199 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 9864431-1 1999 GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). Docetaxel 191-199 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 7945455-0 1994 Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Docetaxel 23-32 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 7945455-7 1994 This polarized transport was inhibited by verapamil, chlorpromazine and reserpine, thus demonstrating that docetaxel is a substrate of P-glycoprotein. Docetaxel 107-116 ATP binding cassette subfamily B member 1 Homo sapiens 135-149 7896535-7 1994 Verapamil modulated docetaxel resistance only in sublines expressing resistance to the drug and overexpressing Pgp. Docetaxel 20-29 ATP binding cassette subfamily B member 1 Homo sapiens 111-114 33799432-6 2021 In addition to increased expression of ABCB1, an ATP-binding cassette (ABC) transporter, and a well-known gene associated with development of docetaxel resistance, we identified genes associated with androgen signaling, cell survival, and overexpression of ncRNAs. Docetaxel 142-151 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 8100632-3 1993 Inhibition of P-glycoprotein by a variety of modulators (verapamil, 1,9-dideoxyforskolin, nifedipine, and taxotere) is associated with an increased vinblastine absorptive permeability. Docetaxel 106-114 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 34928144-1 2022 Targeted concurrent inhibition of intestinal drug efflux transporter P-glycoprotein (P-gp) and drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is a promising approach to improve oral bioavailability of their common substrates such as docetaxel, while avoiding side effects arising from their pan inhibitions. Docetaxel 240-249 ATP binding cassette subfamily B member 1 Homo sapiens 69-83 34928144-1 2022 Targeted concurrent inhibition of intestinal drug efflux transporter P-glycoprotein (P-gp) and drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is a promising approach to improve oral bioavailability of their common substrates such as docetaxel, while avoiding side effects arising from their pan inhibitions. Docetaxel 240-249 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 34928144-5 2022 In vivo, dual P-gp and CYP3A4 inhibitor 3a improved the oral absorption of docetaxel by 3-fold as compared to vehicle, while 3a itself remained poorly absorbed. Docetaxel 75-84 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 34326198-0 2021 Activation of the ABCB1-amplicon promotes cellular viability and resistance to docetaxel and cabazitaxel in castration-resistant prostate cancer. Docetaxel 79-88 ATP binding cassette subfamily B member 1 Homo sapiens 18-23 34268580-8 2021 BBB Pgp activity in the model was optimized using measured CSF data for the Pgp substrates ivermectin, indinavir, vincristine, docetaxel, paclitaxel, olanzapine and citalopram, as no useful in vitro data were available. Docetaxel 127-136 ATP binding cassette subfamily B member 1 Homo sapiens 4-7 34268580-8 2021 BBB Pgp activity in the model was optimized using measured CSF data for the Pgp substrates ivermectin, indinavir, vincristine, docetaxel, paclitaxel, olanzapine and citalopram, as no useful in vitro data were available. Docetaxel 127-136 ATP binding cassette subfamily B member 1 Homo sapiens 76-79 35533911-11 2022 RESULTS: Compared to parental cells, HeLa/Tax cells overexpress P-gp and MRP2 and are approximately 100-360 fold more resistant to the anticancer drugs PTX, docetaxel, and vinblastine. Docetaxel 157-166 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 34439209-2 2021 We assessed the association between ABCB1 amplification and primary resistance to docetaxel or cabazitaxel for patients with mCRPC, using circulating cell-free DNA (cfDNA). Docetaxel 82-91 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 34439209-5 2021 We evaluated the association between ABCB1 amplification or other copy number alterations and primary resistance to docetaxel or cabazitaxel. Docetaxel 116-125 ATP binding cassette subfamily B member 1 Homo sapiens 37-42 34988655-12 2022 CONCLUSION: An association between the ABCB1 C3435T (rs1045642), ABCB1 G2677T/A (rs2032582) polymorphism and risk of adverse effects of docetaxel was found by our meta-analysis. Docetaxel 136-145 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 34988655-12 2022 CONCLUSION: An association between the ABCB1 C3435T (rs1045642), ABCB1 G2677T/A (rs2032582) polymorphism and risk of adverse effects of docetaxel was found by our meta-analysis. Docetaxel 136-145 ATP binding cassette subfamily B member 1 Homo sapiens 65-70 33125673-0 2021 Association of plasma docetaxel levels with ABCB1 gene polymorphisms and tumour response in locally advanced breast cancer patients of South India on neo-adjuvant chemotherapy. Docetaxel 22-31 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 33649517-2 2021 In this study, we aimed to assess the functional significance of 14 polymorphisms in the CYP3A, CYP1B1, ABCB1, ABCC2, and SLCO1B3 genes for the pharmacokinetics and pharmacodynamics of oral docetaxel, co-administered with ritonavir. Docetaxel 190-199 ATP binding cassette subfamily B member 1 Homo sapiens 104-109 33658706-6 2021 Supplementation of cystine (1.0 mM) significantly increased GSH synthesis, rebalanced the redox homeostasis of A549/DTX cells, and reversed DTX-induced upregulation of P-glycoprotein, and it markedly improved the effects of DTX and inhibited the growth of A549/DTX in vitro and in vivo. Docetaxel 140-143 ATP binding cassette subfamily B member 1 Homo sapiens 168-182 33658706-6 2021 Supplementation of cystine (1.0 mM) significantly increased GSH synthesis, rebalanced the redox homeostasis of A549/DTX cells, and reversed DTX-induced upregulation of P-glycoprotein, and it markedly improved the effects of DTX and inhibited the growth of A549/DTX in vitro and in vivo. Docetaxel 140-143 ATP binding cassette subfamily B member 1 Homo sapiens 168-182 33464545-1 2021 INTRODUCTION: ModraDoc006 is a novel docetaxel tablet formulation that is co-administrated with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Docetaxel 37-46 ATP binding cassette subfamily B member 1 Homo sapiens 124-138 33709626-1 2021 BACKGROUND: ModraDoc006 is an oral formulation of docetaxel, which is co-administered with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Docetaxel 50-59 ATP binding cassette subfamily B member 1 Homo sapiens 119-133 33125673-2 2021 The objectives of this study were to assess the effect of ABCB1 gene polymorphisms [SNPs rs1045642 (C3435T) and rs1128503 (C1236T)] on docetaxel plasma levels and also to analyze the influence of docetaxel plasma levels on tumour response in the ethnically distinct South Indian population. Docetaxel 135-144 ATP binding cassette subfamily B member 1 Homo sapiens 58-63 33125673-2 2021 The objectives of this study were to assess the effect of ABCB1 gene polymorphisms [SNPs rs1045642 (C3435T) and rs1128503 (C1236T)] on docetaxel plasma levels and also to analyze the influence of docetaxel plasma levels on tumour response in the ethnically distinct South Indian population. Docetaxel 196-205 ATP binding cassette subfamily B member 1 Homo sapiens 58-63 33125673-11 2021 CONCLUSIONS: The plasma levels of docetaxel were significantly influenced by the SNP C1236T of ABCB1 gene coding for the MDR1 transporter (P-glycoprotein). Docetaxel 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 95-100 33125673-11 2021 CONCLUSIONS: The plasma levels of docetaxel were significantly influenced by the SNP C1236T of ABCB1 gene coding for the MDR1 transporter (P-glycoprotein). Docetaxel 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 33125673-11 2021 CONCLUSIONS: The plasma levels of docetaxel were significantly influenced by the SNP C1236T of ABCB1 gene coding for the MDR1 transporter (P-glycoprotein). Docetaxel 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 139-153 33499040-6 2021 DCX is also a substrate to the drug efflux pump P-glycoprotein (P-gp) that would reduce its concentration within the vicinity of the cells and lead to the development of drug resistance. Docetaxel 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 48-62 33536797-2 2021 Oral docetaxel is co-administered with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir to increase oral bioavailability. Docetaxel 5-14 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 33499040-6 2021 DCX is also a substrate to the drug efflux pump P-glycoprotein (P-gp) that would reduce its concentration within the vicinity of the cells and lead to the development of drug resistance. Docetaxel 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 32748110-0 2020 ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Docetaxel 112-121 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 32756886-16 2020 Conclusions and Relevance: This is the first study, to our knowledge, that identifies an association between a regulatory variant in the ABCB1 gene and the occurrence of pCIA in patients with breast cancer who were treated with docetaxel-based therapies. Docetaxel 228-237 ATP binding cassette subfamily B member 1 Homo sapiens 137-142 32134535-0 2020 Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1. Docetaxel 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 32581798-0 2020 Maslinic Acid Enhances Docetaxel Response in Human Docetaxel-Resistant Triple Negative Breast Carcinoma MDA-MB-231 Cells via Regulating MELK-FoxM1-ABCB1 Signaling Cascade. Docetaxel 23-32 ATP binding cassette subfamily B member 1 Homo sapiens 147-152 32581798-0 2020 Maslinic Acid Enhances Docetaxel Response in Human Docetaxel-Resistant Triple Negative Breast Carcinoma MDA-MB-231 Cells via Regulating MELK-FoxM1-ABCB1 Signaling Cascade. Docetaxel 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 147-152 32134535-5 2020 ABCB1 was detected by using both parental and docetaxel-resistant CRPCs prepared for flow cytometry. Docetaxel 46-55 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 32134535-7 2020 RESULTS: The P-glycoprotein-encoding gene ABCB1 was distinctively upregulated in the resistant cells, and its overexpression played an essential role in docetaxel resistance in CRPC. Docetaxel 153-162 ATP binding cassette subfamily B member 1 Homo sapiens 42-47 31090467-2 2019 However, oral chemotherapy with DTX is also restricted by its active P-glycoprotein (P-gp) efflux and hepatic first-pass metabolism. Docetaxel 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 69-83 31090467-2 2019 However, oral chemotherapy with DTX is also restricted by its active P-glycoprotein (P-gp) efflux and hepatic first-pass metabolism. Docetaxel 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 31090467-3 2019 To address these challenges, we developed a novel SNEDDS co-loaded with DTX and cyclosporine A (CsA) to achieve effective inhibition of P-gp efflux and P450 enzyme metabolization, improving oral bioavailability of DTX. Docetaxel 72-75 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 31090467-3 2019 To address these challenges, we developed a novel SNEDDS co-loaded with DTX and cyclosporine A (CsA) to achieve effective inhibition of P-gp efflux and P450 enzyme metabolization, improving oral bioavailability of DTX. Docetaxel 214-217 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 30814489-10 2019 Mechanistically, FSIP1 bound to the multidrug resistance protein 1 (MRP1) and stabilized it, and knocking out FSIP1 decreased MRP1 expression and increased cellular docetaxel accumulation. Docetaxel 165-174 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 31638462-0 2019 The ABCB1 3435C > T polymorphism influences docetaxel transportation in ovarian cancer. Docetaxel 44-53 ATP binding cassette subfamily B member 1 Homo sapiens 4-9 30637776-0 2019 Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India. Docetaxel 78-87 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 30637776-10 2019 WHAT IS NEW AND CONCLUSION: The tumour response to docetaxel was significantly influenced by the SNP C1236T of ABCB1 gene coding for the P-gp. Docetaxel 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 111-116 30638237-1 2019 Oral chemotherapy of docetaxel (DTX) is restricted by active P-glycoprotein (P-gp) efflux, hepatic first-pass metabolism and then poor oral absorption. Docetaxel 21-30 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 30638237-1 2019 Oral chemotherapy of docetaxel (DTX) is restricted by active P-glycoprotein (P-gp) efflux, hepatic first-pass metabolism and then poor oral absorption. Docetaxel 21-30 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 30638237-1 2019 Oral chemotherapy of docetaxel (DTX) is restricted by active P-glycoprotein (P-gp) efflux, hepatic first-pass metabolism and then poor oral absorption. Docetaxel 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 30638237-1 2019 Oral chemotherapy of docetaxel (DTX) is restricted by active P-glycoprotein (P-gp) efflux, hepatic first-pass metabolism and then poor oral absorption. Docetaxel 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 30638237-6 2019 Moreover, DTX-S-OA showed a comparable ability with verapamil in inhibiting P-gp efflux. Docetaxel 10-13 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 31350703-3 2019 The MDR1 gene was only detected in RMG-1 cells, in which the amounts of Gb4Cer, Leb and GM3 were higher than in the other cells, which reflected their much higher resistance to paclitaxel and docetaxel compared to the other cells. Docetaxel 192-201 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 31350703-6 2019 Thus, MDR1, and increased amounts of Gb4Cer, Leb and GM3 were suggested to be involved in the anticancer drug-resistance to hydrophobic paclitaxel and docetaxel, and GM3 was to basic cisplatin. Docetaxel 151-160 ATP binding cassette subfamily B member 1 Homo sapiens 6-10 29132176-6 2018 Real-time RT-PCR analysis revealed that mdr-1 expression level increased 6 fold with docetaxel (40 nM) and 2 fold with vinblastine (30 nM) after 24 h (p<0.001). Docetaxel 85-94 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 30453546-5 2018 Furthermore, these cells had increased levels of P-glycoprotein (P-gp) and their sensitivity to both docetaxel and cabazitaxel was restored through treatment with tariquidar, a P-gp antagonist. Docetaxel 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 30453546-5 2018 Furthermore, these cells had increased levels of P-glycoprotein (P-gp) and their sensitivity to both docetaxel and cabazitaxel was restored through treatment with tariquidar, a P-gp antagonist. Docetaxel 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 30453546-5 2018 Furthermore, these cells had increased levels of P-glycoprotein (P-gp) and their sensitivity to both docetaxel and cabazitaxel was restored through treatment with tariquidar, a P-gp antagonist. Docetaxel 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 177-181 30453546-6 2018 Results generated demonstrated that P-gp mediated cross-resistance between docetaxel and cabazitaxel. Docetaxel 75-84 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 29885788-12 2018 The variant allele of ABCB1 3435C>T polymorphism could be a potential predictive biomarker of docetaxel-induced rash, and homozygous wild-type ABCB1 2677G>A/T might predict for a greater risk of fatigue. Docetaxel 97-106 ATP binding cassette subfamily B member 1 Homo sapiens 22-27 30555232-13 2018 In addition, PLGA NPs, especially FA incorporated, limited DTX efflux by reducing expression of ABCG2 (3.2-fold) and MDR1 (2.86-fold), which were highly activated by free DTX. Docetaxel 59-62 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 30555232-13 2018 In addition, PLGA NPs, especially FA incorporated, limited DTX efflux by reducing expression of ABCG2 (3.2-fold) and MDR1 (2.86-fold), which were highly activated by free DTX. Docetaxel 171-174 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 30555629-6 2018 One mechanism of chemotherapy resistance was expression of the hypoxia-regulated, drug transporter genes, where especially ABCG2 and MDR1 were shown to be expressed in recurrent prostate cancer and to cause chemotherapy resistance by efficiently transporting drugs like docetaxel out of the cells. Docetaxel 270-279 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 30148955-10 2018 Importantly, drug codelivery in NPs was very efficient in inducing cell mortality also in DTX resistant HeLa-R cells overexpressing P-glycoprotein 1 in which the dose of the chemotherapeutic can be reduced by more than 100 times using DTX/TPCS2a-NPs. Docetaxel 90-93 ATP binding cassette subfamily B member 1 Homo sapiens 132-148 29679509-1 2018 Docetaxel, frequently used for the treatment of breast cancer, is mainly metabolized via hepatic cytochrome P450 (CYP) 3A in humans and is also a substrate of P-glycoprotein (P-gp). Docetaxel 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 159-173 29679509-1 2018 Docetaxel, frequently used for the treatment of breast cancer, is mainly metabolized via hepatic cytochrome P450 (CYP) 3A in humans and is also a substrate of P-glycoprotein (P-gp). Docetaxel 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 175-179 28698198-0 2017 ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Docetaxel 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 28698198-8 2017 In addition, the antiandrogens bicalutamide and enzalutamide, previously demonstrated to be able to resensitize taxane-resistant cells to docetaxel through inhibition of ABCB1 ATPase activity, are also able to resensitize resistant cells to cabazitaxel treatment. Docetaxel 138-147 ATP binding cassette subfamily B member 1 Homo sapiens 170-175 28959367-8 2017 Elacridar (GF120918), a third-generation inhibitor of ABCB1, was able to overcome resistance to docetaxel. Docetaxel 96-105 ATP binding cassette subfamily B member 1 Homo sapiens 54-59 28959367-9 2017 Additionally, knockdown of ABCB1 using small interfering RNA (si)-ABCB1 recovered sensitivity to docetaxel. Docetaxel 97-106 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 28959367-9 2017 Additionally, knockdown of ABCB1 using small interfering RNA (si)-ABCB1 recovered sensitivity to docetaxel. Docetaxel 97-106 ATP binding cassette subfamily B member 1 Homo sapiens 66-71 28959367-11 2017 The results of the present study revealed that docetaxel-resistant NSCLC cells also acquired cross-resistance to EGFR-TKI therapy through mechanisms other than ABCB1, that ABCB1 serves an important role in acquired resistance to docetaxel in lung cancer, and that combination therapy with elacridar can overcome ABCB1-mediated docetaxel resistance. Docetaxel 47-56 ATP binding cassette subfamily B member 1 Homo sapiens 172-177 28959367-11 2017 The results of the present study revealed that docetaxel-resistant NSCLC cells also acquired cross-resistance to EGFR-TKI therapy through mechanisms other than ABCB1, that ABCB1 serves an important role in acquired resistance to docetaxel in lung cancer, and that combination therapy with elacridar can overcome ABCB1-mediated docetaxel resistance. Docetaxel 47-56 ATP binding cassette subfamily B member 1 Homo sapiens 172-177 28959367-11 2017 The results of the present study revealed that docetaxel-resistant NSCLC cells also acquired cross-resistance to EGFR-TKI therapy through mechanisms other than ABCB1, that ABCB1 serves an important role in acquired resistance to docetaxel in lung cancer, and that combination therapy with elacridar can overcome ABCB1-mediated docetaxel resistance. Docetaxel 229-238 ATP binding cassette subfamily B member 1 Homo sapiens 172-177 28959367-11 2017 The results of the present study revealed that docetaxel-resistant NSCLC cells also acquired cross-resistance to EGFR-TKI therapy through mechanisms other than ABCB1, that ABCB1 serves an important role in acquired resistance to docetaxel in lung cancer, and that combination therapy with elacridar can overcome ABCB1-mediated docetaxel resistance. Docetaxel 229-238 ATP binding cassette subfamily B member 1 Homo sapiens 172-177 28959367-11 2017 The results of the present study revealed that docetaxel-resistant NSCLC cells also acquired cross-resistance to EGFR-TKI therapy through mechanisms other than ABCB1, that ABCB1 serves an important role in acquired resistance to docetaxel in lung cancer, and that combination therapy with elacridar can overcome ABCB1-mediated docetaxel resistance. Docetaxel 229-238 ATP binding cassette subfamily B member 1 Homo sapiens 172-177 28959367-11 2017 The results of the present study revealed that docetaxel-resistant NSCLC cells also acquired cross-resistance to EGFR-TKI therapy through mechanisms other than ABCB1, that ABCB1 serves an important role in acquired resistance to docetaxel in lung cancer, and that combination therapy with elacridar can overcome ABCB1-mediated docetaxel resistance. Docetaxel 229-238 ATP binding cassette subfamily B member 1 Homo sapiens 172-177 27629782-5 2016 The development of DTX resistance was also associated with enhanced expression of an ATP-binding cassette (ABC) transporter ABCB1 among the ABC transporter isoforms. Docetaxel 19-22 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 28787019-3 2017 Our group has previously demonstrated that the microtubule dynamics of docetaxel-resistant MCF-7TXT cells are insensitivity to docetaxel due to the distinct expression profiles of beta-tubulin isotypes in addition to the high expression of p-glycoprotein (ABCB1). Docetaxel 71-80 ATP binding cassette subfamily B member 1 Homo sapiens 240-254 28787019-3 2017 Our group has previously demonstrated that the microtubule dynamics of docetaxel-resistant MCF-7TXT cells are insensitivity to docetaxel due to the distinct expression profiles of beta-tubulin isotypes in addition to the high expression of p-glycoprotein (ABCB1). Docetaxel 71-80 ATP binding cassette subfamily B member 1 Homo sapiens 256-261 28938627-4 2017 Transduction of PTOV1 in docetaxel-sensitive Du145 and PC3 cells significantly increased cell survival after docetaxel exposure and induced docetaxel-resistance genes expression (ABCB1, CCNG2 and TUBB2B). Docetaxel 25-34 ATP binding cassette subfamily B member 1 Homo sapiens 179-184 29714413-9 2017 CONCLUSIONS: The elevated expression of AXL enhances the docetaxel-resistance of PC-3 and DU145 prostate cancer cells and AXL intervention improves their chemosensitivity to docetaxel, which may be associated with the increased cell apoptosis in the G2/M phase and decreased expression of ABCB1. Docetaxel 174-183 ATP binding cassette subfamily B member 1 Homo sapiens 289-294 28104912-0 2017 Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation. Docetaxel 76-85 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 28104912-8 2017 By generating a docetaxel-cross-resistant PacR cancer cell line (PacR/DCT), we further clarified the role of FOXO3a in glycolysis-associated mediation of P-glycoprotein/ABCB1 hyperactivity that induces docetaxel cross-resistance. Docetaxel 16-25 ATP binding cassette subfamily B member 1 Homo sapiens 169-174 27629782-6 2016 The combined treatment with inhibitors of the two AKRs and ABCB1 additively sensitized the resistant cells to DTX. Docetaxel 110-113 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 27629782-8 2016 The results suggest that combined treatment with AKRs (1B10 and 1C3) and ABCB1 inhibitors exerts overcoming effect against the cancer resistance to DTX and cisplatin, and can be used as the adjuvant therapy. Docetaxel 148-151 ATP binding cassette subfamily B member 1 Homo sapiens 73-78 27941276-5 2016 Moreover, we found that siRNA mediated ABCB1 knockdown successfully restored drug sensitivity in both paclitaxel and docetaxel resistant esophageal cancer cell lines. Docetaxel 117-126 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 27574448-0 2016 Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Docetaxel 125-134 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 27727250-7 2016 Taken together, our data revealed a novel Notch-1/AP-1/miR-451/MDR-1 signaling axis, and suggested a new therapeutic strategy of combining DTX with Notch inhibitors to treat DTX-resistant LAD. Docetaxel 174-177 ATP binding cassette subfamily B member 1 Homo sapiens 63-68 28642838-8 2016 ABCB1 transport activity can be inhibited by the dietary constituent apigenin and antiandrogens such as bicalutamide which in turn improves response to docetaxel. Docetaxel 152-161 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 27727250-7 2016 Taken together, our data revealed a novel Notch-1/AP-1/miR-451/MDR-1 signaling axis, and suggested a new therapeutic strategy of combining DTX with Notch inhibitors to treat DTX-resistant LAD. Docetaxel 139-142 ATP binding cassette subfamily B member 1 Homo sapiens 63-68